Induced Pluripotent Stem Cell Vaccine Promising for Cancer

Share this content:
Induced Pluripotent Stem Cell Vaccine Promising for Cancer
Induced Pluripotent Stem Cell Vaccine Promising for Cancer

THURSDAY, Feb. 15, 2018 (HealthDay News) -- Induced pluripotent stem cell (iPSC) vaccines prevent tumor growth in syngeneic murine cancer models in a prophylactic setting, according to a study published online Feb. 15 in Cell Stem Cell.

Noting that it may be possible for iPSCs to be harnessed to elicit anti-tumor responses in cancer vaccines, Nigel G. Kooreman, M.D., from the Stanford University School of Medicine in California, and colleagues conducted a proof-of-principle study for using irradiated iPSCs in autologous anti-tumor vaccines.

The researchers found that iPSC vaccines prevented tumor growth in syngeneic murine breast cancer, mesothelioma, and melanoma models in a prophylactic setting. The iPSC vaccine inhibited melanoma recurrence at the resection site as an adjuvant and reduced metastatic tumor load, which was correlated with fewer Th17 cells and increased CD11b+GR1hi myeloid cells. Adoptive transfer of T cells isolated from tumor-bearing mice treated with the vaccine inhibited growth of tumors in unvaccinated recipients.

"Our data suggest a generalizable strategy for multiple types of cancer that could prove highly valuable in clinical immunotherapy," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »